Small molecule-based Lifespan extension therapy: n-3 docosahexaenoic acid (DHA) may prolong mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 26/May/2015, 08.01 am

MiRNA-based growth hormone therapy: miR-130 increases the expression of growth hormone via down regulation of its target gene, 25/May/2015, 23.59
May 25, 2015
Small RNA-based therapy for pulmonary arterial hypertension: MiRNA-10 inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 26/May/2015, 8.15 am
May 26, 2015
Show all

Genome-2-Bio-Medicine Discovery center founder’s father’s (teacher) death anniversary day-26th  May

*********

On the eve of Genome-2-Bio-Medicine Discovery center founder’s father’s (teacher) death anniversary day, we wish to inform you that the ideas posted today (26/May/2015) will be available to the use of Scientists/Professors/Teachers/Physicians/Researchers for free. So, there will be no terms and conditions for the ideas posted today (26/May/2015). Each idea posted will be served first come, first served basis.Write to info@genomediscovery.org for more details. 

 

Dr L Boominathan PhD

President & CSO, GBMD.

*********************************************************************************************

Idea Proposed/Formulated byDr L Boominathan Ph.D.

CitationBoominathan, L., Small molecule-based Lifespan extension therapy: n-3 docosahexaenoic acid (DHA) may prolong mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 26/May/2015, 08.01 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Significance: It has been shown earlier that angiotensin II type I receptor (AT1R) antagonist prolongs mammalian life span. This study suggests, for the first time, that n-3 docosahexaenoic acid (DHA), by increasing the expression of its target gene,  it may suppress the expression of AT1R. And, thereby, it may (1) decrease blood pressure; (2) decrease blood sugar levels; (3) decrease ageing; and (4) extend the lifespan of an individual. Thus, pharmacological formulations encompassing “n-3 docosahexaenoic acid (DHA) or its analogues” may be used to extend the life-span of an individual.

Undisclosed information: How n-3 docosahexaenoic acid (DHA) suppresses the expression of  angiotensin II type I receptor (AT1R)

Comments are closed.